clofibrate has been researched along with Nephrotic Syndrome in 15 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As a consequence, shorter dosing intervals of these drugs seems to be advisable, rather than a reduction in the total daily dose." | 2.35 | Drug protein binding and the nephrotic syndrome. ( Azarnoff, DL; Gugler, R, 1976) |
| "Clofibrate has particular dangers in patients with uraemia or hypoproteinaemia, and we recommend that it be used with great caution in patients with renal disease." | 1.26 | Clofibrate-induced complications in renal disease: a case report. ( Gregory, MC; Pokroy, N; Ress, S, 1977) |
| " No significant differences were seen in the pharmacokinetic parameters observed for antipyrine, a drug which is less than 10% bound to plasms proteins." | 1.25 | Pharmacokinetics of drugs in patients with the nephrotic syndrome. ( Azarnoff, DL; Cohlmia, JB; Gugler, R; Huffman, DH; Shoeman, DW, 1975) |
| "Nephrotic syndrome was induced by a single i." | 1.25 | Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia. ( Edwards, KD; Schapel, GJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (93.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muroya, Y | 1 |
| Ito, O | 1 |
| Walther, A | 1 |
| Mordasini, R | 1 |
| Riesen, W | 1 |
| Bruns, W | 1 |
| Pokroy, N | 1 |
| Ress, S | 1 |
| Gregory, MC | 1 |
| Gugler, R | 2 |
| Azarnoff, DL | 2 |
| Gibaldi, M | 1 |
| Shoeman, DW | 1 |
| Huffman, DH | 1 |
| Cohlmia, JB | 1 |
| Schapel, GJ | 2 |
| Edwards, KD | 4 |
| Bridgman, JF | 1 |
| Rosen, SM | 1 |
| Thorp, JM | 1 |
| Denizot, M | 2 |
| Fabre, J | 2 |
| Pometta, D | 1 |
| Wildi, E | 2 |
| Fredrickson, DS | 1 |
| Neale, FC | 1 |
| Micheli, H | 1 |
| Berthoud, S | 1 |
| Gallt, C | 1 |
| Paoletti, R | 1 |
3 reviews available for clofibrate and Nephrotic Syndrome
| Article | Year |
|---|---|
Drug protein binding and the nephrotic syndrome.
Topics: Antipyrine; Blood Proteins; Clofibrate; Diazepam; Half-Life; Humans; Kinetics; Nephrotic Syndrome; P | 1976 |
A physician's guide to hyperlipidemia.
Topics: Adult; Cholesterol; Chylomicrons; Clofibrate; Diabetes Complications; Diet Therapy; Female; Humans; | 1972 |
Antilipaemic drugs and nephrotic hyperlipidaemia.
Topics: Alkenes; Animals; Blood Protein Disorders; Blood Proteins; Butyrates; Clofibrate; Humans; Hyperchole | 1972 |
12 other studies available for clofibrate and Nephrotic Syndrome
| Article | Year |
|---|---|
Effect of clofibrate on fatty acid metabolism in the kidney of puromycin-induced nephrotic rats.
Topics: Animals; Clofibrate; ERRalpha Estrogen-Related Receptor; Fatty Acids; Hypolipidemic Agents; Kidney; | 2016 |
[Changes in serum lipoproteins in kidney diseases. Therapeutic possibilities].
Topics: Clofibrate; Dietary Fats; Energy Metabolism; Humans; Hyperlipoproteinemias; Kidney Failure, Chronic; | 1983 |
[Secondary hyperlipoproteinemias].
Topics: Acute Disease; Clofibrate; Female; Hepatitis; Humans; Hyperlipidemias; Hypothyroidism; Lipoproteins, | 1977 |
Clofibrate-induced complications in renal disease: a case report.
Topics: Adult; Clofibrate; Humans; Male; Muscular Diseases; Nephrotic Syndrome; Peripheral Nervous System Di | 1977 |
Drug distribution in renal failure.
Topics: Antipyrine; Clofibrate; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Kidney Failure, Ch | 1977 |
Pharmacokinetics of drugs in patients with the nephrotic syndrome.
Topics: Adult; Antipyrine; Blood Proteins; Body Weight; Clofibrate; Dose-Response Relationship, Drug; Female | 1975 |
Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
Topics: Animals; Body Weight; Butyrates; Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Drug Eva | 1975 |
Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia.
Topics: Adult; Binding Sites; Blood Protein Disorders; Clofibrate; Female; Fructose-Bisphosphate Aldolase; H | 1972 |
Clofibrate, nephrotic syndrome, and histological changes in muscle.
Topics: Adult; Clofibrate; Humans; Male; Muscles; Muscular Diseases; Nephrotic Syndrome | 1973 |
Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic hyperlipidaemia.
Topics: Adolescent; Adult; Alkenes; Blood Pressure; Butyrates; Cholesterol; Cholestyramine Resin; Clofibrate | 1974 |
[Hypolipemic property and myotoxic action of clofibrate in a case of nephrotic syndrome].
Topics: Adult; Arteriosclerosis; Cholesterol; Clofibrate; Glomerulonephritis; Humans; Hyperlipidemias; Male; | 1973 |
Serum phospholipid alterations and their control by chlorophenoxyisobutyrate and betabenzalbutyrate in puromycin aminonucleoside induced nephrotic syndrome in the rat.
Topics: Animals; Anticholesteremic Agents; Butyrates; Cholesterol; Cholestyramine Resin; Clofibrate; Female; | 1970 |